Why is Marksans Pharma falling/rising?

As of 16-Sep, Marksans Pharma Ltd's stock is currently priced at 176.10, reflecting an increase of 1.85 (1.06%). The stock has shown a positive trend recently, gaining 1.79% over the last two days and outperforming its sector by 0.78% today. However, despite this short-term gain, the stock has underperformed over the past month with a decline of 1.23%, and a significant year-to-date drop of 40.56%. The company has a high management efficiency indicated by a return on equity (ROE) of 17.66% and a low debt-to-equity ratio, which may support investor confidence. Nevertheless, the company has faced challenges, including a decline in operating profit and negative quarterly results, which have contributed to its long-term struggles.
In the broader market context, the stock's recent performance contrasts with the benchmark, as it has gained 2.18% over the past week compared to the Sensex's 1.58% increase. However, the stock's year-to-date performance is significantly worse than the market's overall gain of 5.43%. The stock's liquidity remains adequate for trading, but a notable decline in delivery volume suggests waning investor participation. While institutional holdings are relatively high, indicating some level of confidence, the overall negative sentiment stemming from poor long-term growth and high valuation metrics may continue to weigh on the stock's performance.